DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Gastroesophageal Reflux Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Gastroesophageal Reflux Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Gastroesophageal Reflux Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Gastroesophageal Reflux Disease: An Overview
Gastroesophageal reflux disease (GERD) is a digestive disorder that occurs when acidic stomach juices, or food and fluids back up from the stomach into the esophagus. GERD is the regular, persistent, and long-term occurrence of GER. GERD is caused by multiple different mechanisms that can be intrinsic, structural, or both, leading to the disruption of the esophagogastric junction barrier resulting in exposure of the esophagus to acidic gastric contents.
Acid reflux happens when the lower esophageal sphincter (LES) does not tighten or close properly. This allows digestive juices and other contents from the stomach to rise up into the esophagus. If the sphincter relaxes abnormally or weakens, stomach acid can flow back up into your esophagus. This constant backwash of acid irritates the lining of your esophagus, often causing it to become inflamed.
Gastroesophageal Reflux Disease progresses through distinct stages: from heightened esophageal sensitivity to erosive GERD, and further complications. Reflux hypersensitivity, an initial stage, presents typical heartburn symptoms without tissue damage. Symptomatic non-erosive gastroesophageal reflux disease (sGERDi) involves reflux symptoms but lacks visible tissue harm. Erosive GERD, or esophagitis, denotes tissue damage and erosions due to stomach acid. Complicated GERD encompasses ulcers, strictures, or Barrett’s esophagus as advanced complications.
GERD treatment aims to cut down on the amount of reflux or lessen damage to the lining of the esophagus from refluxed materials. Some medications to treat GERD include:- Antacids, H2 Blockers, Proton pump inhibitors (PPIs), and Prokinetics. Diet and lifestyle changes are also recommended to help manage GERD.
In May 2023, Phathom Pharmaceuticals announced that it had resubmitted its New Drug Application for vonoprazan for the treatment of Erosive GERD also referred to as erosive esophagitis to the FDA.
Gastroesophageal Reflux Disease Market Key Facts
-
As per Marco G Patti (2020), 25%-40% of Americans experience symptomatic GERD at some point and about 7%-10% of Americans experience symptoms of GERD on a daily basis. Many individuals control their symptoms with over-the-counter (OTC) medications and without consulting a medical professional, the actual number of individuals with GERD is probably higher.
-
In the study by Savarino et al. (2017), Gastroesophageal Reflux Disease exhibits two primary phenotypic forms: erosive reflux disease (ERD) and non-erosive reflux disease (NERD), with NERD encompassing the majority of cases (up to 70%). Over time, both NERD and mild esophagitis generally remain stable. Transition rates between phenotypic stages are relatively low, with NERD to ERD progression ranging from 0% to 30%, mild to severe ERD from 10% to 22%, and ERD to Barrett’s esophagus from 1% to 13%.
-
As per the article by Peter W. Dettmar et al. (2014), the prevalence of GERD is 10–20% in Europe and the US, but less than 5% in Asia. An estimated 60–70 million Americans are affected by gastrointestinal diseases annually. It is also estimated that 40% of the US population experiences GERD symptoms, with 10–20% of people being affected on a weekly basis.
Gastroesophageal Reflux Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Gastroesophageal Reflux Disease pipeline therapies. It also thoroughly assesses the Gastroesophageal Reflux Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Gastroesophageal Reflux Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Gastroesophageal Reflux Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Gastroesophageal Reflux Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Gastroesophageal Reflux Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Gastroesophageal Reflux Disease Epidemiology, Segmented as –
-
Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
-
Diagnosed Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
-
Treatable Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
-
Age-specific Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
-
Phenotype-specific Prevalent Cases of Gastroesophageal reflux disease in the 7MM [2019–2032]
Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to be launched during the study period. The analysis covers the Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Gastroesophageal Reflux Disease drugs based on their sale and market share.
The report also covers the Gastroesophageal Reflux Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Gastroesophageal Reflux Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Gastroesophageal Reflux Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
Gastroesophageal Reflux Disease Therapeutics Analysis
The current treatment paradigm for GERD consists of lifestyle modification, pharmacological control of gastric acid secretion, or anti-reflux surgery. In recent years, several minimally invasive antireflux endoscopic therapies (ARET) have been developed, which may play a role in bridging the unmet therapeutic gap between medical and surgical treatment options.
Several major pharma and biotech companies are developing therapies for Gastroesophageal Reflux Disease (GERD). Currently, Onconic Therapeutics is leading the therapeutics market with its Gastroesophageal Reflux Disease (GERD) drug candidates in the most advanced stage of clinical development. Vonoprazan, BLI510, naronapride, and other highly anticipated future medicines are all presently awaiting approval. These promising medicines are currently in the late phases of clinical studies.
Gastroesophageal Reflux Disease Companies Actively Working in the Therapeutics Market Include
-
Cinclus Pharma
-
Onconic Therapeutics
-
Renexxion
-
Addpharma
-
Trio Medicines
-
Chong Kun Dang Pharmaceutical
-
HK inno.N Corporation
And Many Others
Emerging and Marketed Gastroesophageal Reflux Disease Therapies Covered in the Report Include:
-
X842: Cinclus Pharma
-
Zastaprazan: Onconic Therapeutics
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Gastroesophageal Reflux Disease Competitive Intelligence Analysis
4. Gastroesophageal Reflux Disease Market Overview at a Glance
5. Gastroesophageal Reflux Disease Disease Background and Overview
6. Gastroesophageal Reflux Disease Patient Journey
7. Gastroesophageal Reflux Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Gastroesophageal Reflux Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Gastroesophageal Reflux Disease Unmet Needs
10. Key Endpoints of Gastroesophageal Reflux Disease Treatment
11. Gastroesophageal Reflux Disease Marketed Therapies
12. Gastroesophageal Reflux Disease Emerging Drugs and Latest Therapeutic Advances
13. Gastroesophageal Reflux Disease Seven Major Market Analysis
14. Attribute Analysis
15. Gastroesophageal Reflux Disease Market Outlook (In US, EU5, and Japan)
16. Gastroesophageal Reflux Disease Companies Active in the Market
17. Gastroesophageal Reflux Disease Access and Reimbursement Overview
18. KOL Views on the Gastroesophageal Reflux Disease Market
19. Gastroesophageal Reflux Disease Market Drivers
20. Gastroesophageal Reflux Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/gastroesophageal-reflux-disease-gerd-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“West Nile Encephalitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the West Nile Encephalitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the West Nile Encephalitis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices
The post Gastroesophageal Reflux Disease (GERD) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Cinclus, Onconic, Renexxion, Addpharma, Trio Medicines first appeared on PressRelease.cc.
Gastroesophageal Reflux Disease (GERD) Market: Latest Study by DelveInsight Reveals a Lucrative Investment Opportunity and Growth Prospect | Cinclus, Onconic, Renexxion, Addpharma, Trio Medicines first appeared on Web and IT News.